Trade name ‘The Stem Cell Group’ registered for Celulas Genetica

Emerging Healthcare Solutions, Inc. (PinkSheets:EHSI) announced today that it registered a trade name, "The Stem Cell Group," for use in marketing and branding its subsidiary company, Celulas Genetica.

“Celulas Genetica will play a crucial role in the development of the Rutherford Procedure”

Celulas Genetica is a biotechnology firm that EHSI acquired last December. Headquartered in Panama City, Panama, Celulas Genetica is a Central American leader in stem-cell technology acquisition and development. The company was acquired by EHSI after purchasing a license to develop and market the Rutherford Procedure, a groundbreaking organ regeneration treatment designed to use proton-beam technology to destroy diseased organ tissue for regeneration using adult stem cells.

"Celulas Genetica will play a crucial role in the development of the Rutherford Procedure," said EHSI President and CEO Cindy Morrissey. "Under the trade name 'The Stem Cell Group,' we believe this important subsidiary of EHSI will be more attractive to potential partners and investors around the world."

In January, Celulas Genetica opened a new business office located in the Chaoyang District of Beijing, a region of the Chinese capital that is home to many foreign embassies and business headquarters. It was a crucial first step for the company in its mission to test and perfect the Rutherford Procedure using EHSI's NASA bioreactor.

The Intrifuge Rotary Cell Culture System^TM, a rotating-wall bioreactor originally designed by NASA to facilitate the growth of human stem cells in simulated weightlessness, is key to EHSI's plan to commercialize and develop The Rutherford Procedure. Stem cell cultures grown inside the bioreactor look and function much closer to cells grown within the body than cell cultures grown in Petri dishes.

Earlier this year, EHSI acquired a license to use the bioreactor to expand adult stem cells in China and elsewhere outside of the U.S. Stem cell expansion is a crucial component of the Rutherford Procedure, as a multitude of high-quality adult stem cells is extremely beneficial for regenerating patients' damaged livers into healthy, functioning organs once more.

For more information on Celulas Genetica and the Rutherford procedure, please visit http://www.TheStemCellGroup.com.

The Stem Cell Group is planned to serve as a major outpost in EHSI's global footprint. In addition to the Stem Cell Group's headquarters in Panama and business office in China, EHSI also maintains offices in Germany and Poland.